Twist Bioscience Corporation TWST
140.30 USD +11.26 (+8.73%)
At closeNov 3, 2026, 7:42 PM EST
138.69 -1.61 -1.14%
After hours · Nov 3, 7:42 PM ET
130.22 Day range 141.62
23.30 52-week range 219.71
- YTD
- +342.31%
- 1 year
- +344.41%
Analyst view
Consensus: buy
Buy
Price target (mean) 168.25 +19.9% upside
Now 140.30
- Target (low)
- 45.00
- Target (mean)
- 168.25
- Target (high)
- 215.00
Ratings (0m) 13 9 buy · 3 hold · 1 sell
- Strong buy2
- Buy7
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.203 | -0.382 – -0.02 | -0.45 | +54.9% | 123.58M | +24.8% | 4 |
| Next quarter | -0.138 | -0.314 – -0.04 | -0.50 | +72.4% | 126.42M | +21.9% | 3 |
| Current year | -1.20 | -2.14 – -0.57 | -2.12 | +43.5% | 456.30M | +21.2% | 5 |
| Next year | -0.40 | -1.12 – 0.10 | -1.20 | +66.6% | 548.64M | +20.2% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 8, 2026 | Jefferies | Initiated | — | Hold |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 29, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 18, 2026 | BWS Financial | Maintained | Sell | Sell |
| Sep 17, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Sep 9, 2026 | BWS Financial | Initiated | — | Sell |
| Sep 9, 2026 | UBS | Initiated | — | Neutral |
| Aug 5, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 4, 2026 | Baird | Maintained | Outperform | Outperform |
| Jul 14, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 6, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Jun 29, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jun 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 15, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jun 15, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Jun 11, 2026 | Piper Sandler | Initiated | Overweight | Overweight |
| May 5, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform |
| May 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 5, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 5, 2026 | Baird | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Mar 30, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 3, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Feb 3, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 26, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 8, 2026 | TD Cowen | Maintained | Buy | Buy |